Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Postpartum Depression
NCT04950868Phase 1Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quetiapine in postpartum depression (PPD). Primary endpoints: Recruitment and retention rate at 10 weeks, Blood pressure at 8 weeks and 8 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
quetiapine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT04950868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950868.